odevelopmental groups (developmental disorders), which is characterized mainly by three symptoms of carelessness, hyperactivity and impulsivity, and is a disorder of brain function which can be treated by psychosocial treatment, support and pharmacotherapy. In dsm-5, the preva lence of children's ADHD is 5% and adults are 2.5 percent.
1.Intunib concluded on November 18, 2011 between Shionogi and shirabe PLC (Headquarters: Dublin Ireland, CEO: framing orthorov), based on the licensing agreement on joint development and commercialization in Japan.
Intunib is the first action mechanism as an ADHD drug, "selective α 2A adrenoceptor agonist", and is a non central stimulant administered once a day. In the prefrontal cortex of the ADHD patient, the activation level of the postsynaptic α 2A receptor is low, and the signal transduction may be attenuated. Although the mechanism of action of guanfamine against ADHD is not yet clear, it is suggested from non clinical studies that it selectively stimulates attenuated signal transduction by selectively stimulating the postsynaptic α 2A adrenoceptor. The mechanism of action of imitinib is different from the action mechanism of the drug which has been sold as an ADHD drug in Japan so far, and it is expected to be a new treatment option of the ADHD patient. Instinct from shaver to 2017
|
